Bajpai et al. [16] highlighted the feasibility of monoclonal antibody-based therapies for HER-2/neu-positive cervical cancers, emphasizing the need for standardized testing protocols to identify eligible patients. This evidence concerns the gene ERBB2 and cervical carcinoma.